Loading
KSQ-4279 is an experimental drug from KSQ Therapeutics, in phase 1 trials for advanced solid tumours.
KSQ-4279 is a small molecule from KSQ Therapeutics. A selective inhibitor of USP1, an enzyme that helps regulate the repair of damaged DNA. KSQ licensed it worldwide to Roche in July 2023, and the registry now names it RO7623066. Its completed phase 1 study (NCT05240898) tested it alone and with olaparib or carboplatin. OnCo has no USP1 target record. Whether it works in people has not been established.
A selective inhibitor of USP1, an enzyme that helps regulate the repair of damaged DNA.
1.KSQ-4279 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KSQ-4279" OR ABSTRACT:"KSQ-4279" OR TITLE:"RO7623066" OR ABSTRACT:"RO7623066" OR TITLE:"RG6614" OR ABSTRACT:"RG6614") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KSQ-4279, not a curated reading list.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/